“Myrtelle” or the “Company”, a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the…
Juno Pharmaceuticals Canada (“Juno”), a Canadian specialty pharmaceutical company, announced its partnership with U.K. based developer, manufacturer and global supplier of novel, Rx, oral liquid medicines, Rosemont Pharmaceuticals (“Rosemont”), as…
Juno Pharmaceuticals Canada (« Juno »), une société pharmaceutique canadienne spécialisée, annonce son partenariat avec Rosemont Pharmaceuticals (« Rosemont ») pour devenir son distributeur canadien exclusif. Rosemont est une entreprise…
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the sale to OMERS, one of Canada’s largest defined benefit…
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief…
MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc. The collaboration will allow for the…
NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that Mindful Care, the first-ever same-day mental health company focused on providing urgent psychiatric care,…
Veristat, une organisation mondiale de recherche clinique (CRO) à l’esprit scientifique, a félicité aujourd’hui HIPRA pour l’autorisation de mise sur le marché par l’Agence européenne des médicaments (EMA) et la Commission européenne…
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2 clinical study of ARO-RAGE, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of…
Life Edit® Therapeutics Inc., an ElevateBio® company focused on next-generation gene editing technologies and therapeutics, today announced the presentation of the first preclinical data from the company’s Huntington’s disease program across three…
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity.…
Albatroz Therapeutics, a biotechnology company targeting tissue remodeling to stop cancer growth and treat arthritis, today announced it has secured $3 million USD in funding led by Outram Bio and…